Presenting Companies

42 Health Sensors

Robert Sheldon, President Calgary, AB Category: Devices, Diagnostics & Clinical Decision Support

Presented by: CANet

42 Health Sensors, a University of Calgary spin-off, is developing small, continuously active, multimodal, wearable physiologic sensors for home and clinical use. They will put useful information in the hands of their owner users, when and where they need it. The overall potential market includes 120 million North Americans, and wearable monitors provide best care. We have unique, protected technological edges for the holy grail of wearable sensors: continuous blood pressure sensing. 42 Health Sensors is entering clinical studies in January 2020 and is fundraising to support clinical studies, device hardware and firmware refinement, intellectual property protection, and regulatory approval.

Aifred Health

Marina Massingham, CEO Montréal, QC Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Montréal InVivo

Aifred Health focuses on clinical decision support in mental health, starting with Depression. We have pilots running at 2 hospital sites in Canada today and negotiating a further 3, 2 of which are in Boston and Pittsburgh. We successfully raised a pre-seed in May and are looking to raise Seed in Q1, with the goal of commercializing our first generation product and getting our second (AI-based) through FDA approval.

Arctic Fox AI

Jeremi Lavoie, CEO Montréal, QC Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Montréal InVivo

Arctic Fox is an applied AI software company specializing in the detection of abnormalities in neuroimaging. Its mission is to make the diagnosis of common brain diseases faster, cheaper and more reliable. The company was founded in Montreal in 2018 and is a Techstars AI alumnus. It works in partnership with the Montreal Neurological Institute (MNI), the Montreal Institute for Learning Algorithms (MILA) and the University of Montreal Health Center (CHUM).  

Aufero Medical

Daniel Gelman, President & CEO London, ON Category: Devices, Diagnostics & Clinical Decision Support

Presented by: CANet

Aufero Medical is a spin-out of Western University, developing a small device for the treatment of cardiac arrhythmia. The device adds onto the surgeon’s catheter to monitor and stabilize the force between the tip of the catheter and the moving heart, removing the effects of heart motion, a major cause of failed heart ablation procedures. The global market for catheter ablation devices for atrial fibrillation is expected to grow from $3.9B to $7.0B (12.6% CAGR) over the next five years. Aufero is fundraising to support the commercialization of this technology, which will reduce arrhythmia recurrence and repeat surgeries.

Axem Neurotechnology

Christopher Friesen, Co-Founder & CTO Halifax, NS Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Innovacorp

Helping stroke specialists maximize patient outcomes by providing neurotechnology-enabled, at-home physical therapy, as well as remote monitoring of stroke recovery and rehabilitation. Stroke survivors are guided through their home exercise program while a patent-pending device provides encouraging feedback that they are activating the right brain areas to promote recovery. Providers can track patient adherence and recovery objectively, manage rehabilitation remotely, and share data with payers. Proof of concept established, first clinical (and several other pilot) studies ongoing. Raising seed round to complete clinical studies (sites/PIs identified) and gain FDA clearance.

BioInteractive Technologies

Lukas-Karim Merhi, CEO & Co-Founder Vancouver, BC Category: Devices, Diagnostics & Clinical Decision Support

BioInteractive Technologies, endorsed by the Mayo Clinic & Techstars, is a Medical Device and Digital Health company developing intelligent wearables to revolutionize physical therapy for injuries such as Rheumatoid Arthritis, Stroke, Wrist Fractures, Carpal Tunnel Syndrome and Tennis/Golfer’s Elbow; a $12B market in the US alone. BIT’s patent-pending TENZR technology powers a wristband that understands the injury, helps people recover, and stop the reoccurrence. We are raising $2M CAD Seed round on a convertible note - 600K is left. The funds will be used to roll-out of TENZR to Physical Therapy Clinics and run Clinic Trials with Mayo Clinic.

CNA Diagnostics

David Gordon, CEO Calgary, AB Category: Devices, Diagnostics & Clinical Decision Support

CNA Diagnostics Inc. is a molecular diagnostics company developing diagnostic tests for the early detection of disease in humans and animals prior to the onset of observable clinical symptoms. CNAD’s diagnostic platform focuses on comparative changes in circulating nucleic acid (CNA) sequences in a patient’s diseased state and uses bioinformatics to identify unique biomarkers.

CNAD develops diagnostic kits (based on standard PCR technologies) and decision-making algorithms that convert complex body signaling systems into easy to interpret diagnostic results for improved patient treatment outcomes.

Cohesys

Michael Floros, CEO Toronto, ON Category: Devices, Diagnostics & Clinical Decision Support

Cohesys has developed BoneTape, a novel bone fracture fixation technology that provides an easy-to-use, flexible, low-profile, biocompatible, and bioresorbable system for the alignment and stabilization of non-loadbearing craniomaxillofacial fractures. BoneTape would replace titanium plates & screws in these surgeries. Validation has been conducted in ex vivo rabbit fracture stabilization, as well as BoneTape submerged in blood and various simulated biological fluids. Cohesys will be completing small animal studies in 2019 and raising a Series A in 2020 to fund an FDA 510k regulatory application, manufacturing scaleup, and initial sales in the US.

Cosm Medical

Derek Sham, Founder & CEO Toronto, ON Category: Devices, Diagnostics & Clinical Decision Support

Pelvic Floor disorders are common, growing and underserved. They include prolapse and incontinence which affects half of all women by 80 years of age. Surgery in this field has major issues that led the FDA to ban surgical mesh in Apr 2019; conservative therapy with gynaecological prosthetics, known as pessaries, come in 100+ shapes and sizes fit by trial and error. Cosm Medical is leveraging data science to combine a new ultrasound technology with 3D printing to create Gynethotics, or the world’s first custom gynecological prosthetic so more woman can live and age with dignity and grace.

Densitas

Mo Abdolell, Founder & CEO Halifax, NS Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Innovacorp

Densitas’ vision is to move the needle in breast cancer screening through individualized patient management for sustainable healthcare service delivery. Densitas develops advanced AI-powered solutions that deliver on-demand actionable insights through point-of-care and advanced healthcare analytics for breast health management aimed at improved patient outcomes. The densitasai™ platform, comprising densitas densityai™, densitas qualityai™ and densitas riskai™ tackles pressing challenges facing breast cancer screening today, including precision breast health, mammography quality, workflow efficiencies, compliance with national standards, and meeting accreditation requirements. In September 2019, Densitas won procurement of its densitas densityaiTM software for deployment in as many as 24 clinic across Germany as part of the DIMASOS 2 Trial.

INViCARE

Ashwaq Al-Hashedi, Founder & CEO Montréal, Quebec Category: Devices, Diagnostics & Clinical Decision Support

Presented by: McGill University

INViCARE is a nanotechnological spin-off company of McGill University, bringing innovative and impactful biomaterials to the healthcare industry, starting with the dental implant care market. The company’s leading technology is a proprietary nanocrystalline gel with proven implant disinfection and bone healing properties, the result of seven years of collaborative work between researchers at McGill University, Harvard University and Université de Montréal. 

The first product (NeoPhylaxis) is initially targeting the $7B North America market. It is implemented in 10 clinics in Montreal to clean implants, reduce the rate of infections, alleviate people's suffering and lower healthcare costs. INViCARE is currently raising funds to commercialize this product and investigate other potential applications of our nanocrystalline technology.

MEDSTACK

Balaji Gopalan, CEO & Co-Founder Toronto, ON Category: Devices, Diagnostics & Clinical Decision Support

MedStack is a HIPAA-compliant privacy solution for digital health application developers that helps innovators get to market up to 60% faster. Since our launch in 2015 our revenues have grown by 3,373%. In February 2019, we raised a $2.4MM CAD oversubscribed seed round led by TELUS Ventures and we are currently seeking Series A funding to continue driving brand awareness, delivering a top-notch user experience, building a delightful onboarding experience, and expanding our reach geographically outside of Canada and the US.

Metabolomic Technologies

Kaushik Srinivasan, CEO Edmonton, AB Category: Devices, Diagnostics & Clinical Decision Support

Metabolomic Technologies Inc. (MTI) is a small but growing company developing metabolomics-based in vitro diagnostics. Our lead product, PolypDx™ is the first and only urine-based screening test for colorectal cancer. PolypDx is now being assessed by the provincial health system in Alberta, as a way to increase screening rates for colorectal cancer. In the US market, after receiving US patent coverage and CMS gapfill status as a novel test, we are now focused on FDA approval and reimbursement. Our current Series A raise will be used to fund a multicenter pivotal trial in the US with various prestigious health systems.

NERv Technology

Amr Abdelgawad, COO Waterloo, ON Category: Devices, Diagnostics & Clinical Decision Support

NERv is a medical device startup developing a sensory platform designed to detect gastrointestinal leaks that can arise after surgical procedures. The company is raising a seed round of 3,000,000 CAD. The funding would go towards completing clinical studies and regulatory submissions in the United States and Canada.

Neuraura Biotech

Claire Dixon, COO Calgary, AB Category: Devices, Diagnostics & Clinical Decision Support

Neuraura is unlocking the field of brain machine interface with next generation microsensors that eclipse the performance of legacy sensors in terms of precision in recording and stimulation. Neuraura’s beachhead clinical application is an epilepsy surgery system which will provide unique access to deep brain insight, our source of long-term competitive advantage and has a Class II 510(k) regulatory path. Neuraura is seeking investors for a $4M+ equity round to commercialize the epilepsy surgery system and, in parallel, complete small-scale in-human trials. This funding will enable Neuraura to expand the core team as well as set up initial assembly/manufacturing operations.

ODS Medical

Christopher Kent, President & CEO Montréal, QC Category: Devices, Diagnostics & Clinical Decision Support

Presented by: McGill University

ODS Medical is bringing to market a revolutionary handheld optics probe which identifies cancerous tissue in real-time during solid tumor surgeries directly in the patient. Using Raman spectroscopy signatures, this optical biopsy technique relies on machine learning for cancer detection. Our technology gives the surgeon the ability to find and remove areas of tumor that previously went undetected, all within a fraction of a second. Because of its disruptive potential in minimally invasive surgery and surgical robotics, we have already established commercial partnerships with world-class medical device companies. Raising a bridge round to finish product development and initial clinical assessment.

Qidni Labs

Morteza Ahmadi, CEO Waterloo, ON Category: Devices, Diagnostics & Clinical Decision Support

Qidni Labs is developing the world's smallest blood purification system for millions of patients with kidney failure. The technology will be a dual-use at home portable/wearable blood purification device that replaces dialysis, provides more frequent therapy and significantly improves the quality of life for kidney failure patients. The company is raising a Series A to support completion of pre-clinical tests required for US regulatory approval; and performing experiments to generate data as scientific evidence.

RetiSpec

Eliav Shaked, CEO Toronto, ON Category: Devices, Diagnostics & Clinical Decision Support

RetiSpec has developed a non-invasive, simple to use and inexpensive tool for detection of early Alzheimer’s disease biomarkers in the eye based on machine learning, paving the way for widely adopted screening. Fundraising proceeds will be used to support commercialization and growing the team.

SaluTech

Shuhe Li, CEO Toronto, ON Category: Devices, Diagnostics & Clinical Decision Support

SaluTech has developed a patent-pending conductive biomaterial (CBM) to effectively treat Atrial Fibrillation by resynchronizing the erratic electrical signals in the atria. CBM is a non-toxic, long-lasting, and biocompatible nano-membrane that mimics the conductive velocity of healthy heart tissue. SaluTech is currently completing large animal studies using non-dilutive research grants, progressing the business development using our pre-seed fundraising, and looking to move forward to starting clinical trials.

Spring Loaded Technology

Christopher Cowper-Smith, CEO Dartmouth, NS Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Innovacorp

Spring Loaded is an award-winning company focused on mobility-restoring bionics. The company incorporates its patented liquid spring technology into Levitation®, the world’s first compact and powerful bionic knee brace. Levitation® is the only Tri-Compartment UnloaderTM brace that can significantly reduce pressure throughout the knee while enhancing strength to alleviate pain and improve mobility for people with knee arthritis and injuries.

Spring Loaded is generating revenue from across Canada and the United States. The company will soon be raising a Series A financing of approximately $5,000,000. Proceeds will be used to scale up revenues and diversify the spring loaded product offering.

Vena Medical

Michael Phillips, CEO Kitchener, ON Category: Devices, Diagnostics & Clinical Decision Support

Vena Medical is a pre-clinical-stage device company that is providing physicians with the world's smallest camera capable of going inside veins and arteries to help them treat stroke. Open surgeries are rapidly being replaced by minimally invasive procedures and Vena Medical's technology is leading the way. Vena will be raising Series A financing to submit regulatory approvals and reach early revenue.  

Adapsyn

Andy Haigh, President & COO Hamilton, ON Category: Therapeutic

Adapsyn Bioscience has developed a next generation bioinformatics platform devoted to discovering previously unidentified evolved natural products for use as human therapeutics. The company applies proprietary machine learning algorithms to genomic and metabolomic data to reveal novel drug-like compounds encoded by microbial genomes. The technology is being applied to find new drugs in the fields of oncology; bacterial, fungal and viral infection; autoimmune disorders; cardiovascular and lipid metabolism disorders; neuroscience; and others. The company is seeking funding for continued drug discovery and development efforts and for general corporate purposes.

Allarta Life Science

Harold Stover, Co-founder & CEO Hamilton, ON Category: Therapeutic

Presented by: McMaster University

A pre-clinical stage life science company, developing proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia.

Aspect Biosystems

Tamer Mohamed, President & CEO Vancouver, BC Category: Therapeutic

Presented by: Stem Cell Network

Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery, and regenerative medicine products.

Elarex

Robert DeWitte, Co-Founder & CEO Hamilton, ON Category: Therapeutic

Presented by: McMaster University

Elarex is a biotechnology company commercializing its PT120 formulation technology which dramatically stabilizes a wide range of biologics. Our mission is to free vaccines from the cold chain, a $20B drain on global healthcare spending. Our prototype has demonstrated breakthrough performance in animal studies of multiple vaccines and leading vaccine and life sciences companies have begun to engage in strategic dialogue. We will raise $2M in Q2 2020 to refine prototype design based on customer input, prepare manufacturing process for scale up, strengthen IP estate, strengthen leadership team, execute collaborative projects with customers, and secure major development partnerships.

Empirica Therapeutics

Parvez Vora, Director, Preclinical Development Hamilton, ON Category: Therapeutic

Empirica Therapeutics is developing a pipeline of innovative and transformative immunotherapies for cancers of high unmet need. As an early-stage preclinical biotechnology company, Empirica is seeking Seed/Series A funds, along with strategic alliances to accelerate its transformation into a fully-sustainable organization. The Company has secured an initial $1.8M in capital through its partnership with Centre for the Commercialization of Antibodies and Biologics (CCAB) and the Centre for Commercialization of Regenerative Medicine (CCRM). Additional financing is being sought, and the Company is entering into due diligence phase with some Canadian VCs, and in discussions with multiple VCs for both, additional seed and Series A financing.

ExCellThera

Emil Vanjaka, Operations & Business Development Manager Montréal, QC Category: Therapeutic

Presented by: Stem Cell Network

ExCellThera is an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases. ExCellThera’s lead solution combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. ExCellThera is looking to raise $35M to fund the key clinical trials fueling its development pipeline to support a target commercialization of its lead product, ECT-001, by 2022.

Giiant Pharma

Bernard Côté, Co-Founder and Chief Operating Officer Montréal, QC Category: Therapeutic

Presented by: Montréal InVivo

Giiant Pharma is a Montreal-based virtual company founded by former Merck Frosst scientists Dr. Elizabeth Kwong and Dr. Bernard Côté. Our main driver is to improve on drug tolerability of anti-inflammatory agents using innovative tissue-specific delivery strategies. In 2016, Giiant Pharma initiated the project “Colon-specific delivery of PDE4 inhibitor prodrugs for the treatment of ulcerative colitis” which has recently led to the identification of the pre-clinical candidate GT-2108. The company is currently seeking for CAD $12 M funding to support IND-enabling studies up to Ph-Ib human proof-of-concept with GT-2108 in moderate-to-severe ulcerative colitis patients.

HitchHike Therapeutics

Derrick Gibbings, CEO Ottawa, ON Category: Therapeutic

Presented by: University of Ottawa, Faculty of Medicine

HitchHike Therapeutics harnesses evolution to deliver RNA and novel protein therapeutics to tissues beyond the liver.  HitchHike’s proprietary technology engineers cells to manufacture exosomes at scale that are already packaged with up to 1000-fold more RNA or proteins. HitchHike exosomes are intact enabling safe delivery to multiple tissues beyond liver with much lower doses than best-in-class lipid nanoparticle or exosome competitors.

Immune Biosolutions

Frédéric Leduc, CEO Montréal, QC Category: Therapeutic

Presented by: Montréal InVivo

Immune Biosolutions is an innovative biotech company focused on the discovery and engineering of therapeutic humanized chicken antibodies targeting difficult proteins with a validated, yet unexploited, therapeutic potential.

KisoJi Biotechnology

David Young, CEO & Co-Founder Laval, QC Category: Therapeutics

KisoJi is a venture backed next generation antibody company developing multi-specific antibodies to improve outcomes in oncology. KisoJi uses its proprietary single domain antibody (sdAb, VHH) platform technologies to create a pipeline of first-in-class anti-cancer antibodies. Our lead tri-specific antibody (D2 x PD1 x CD3) is entering manufacturing in 2020 and an IND in 2021 targeting solid tumors, especially small cell lung cancer. It incorporates breakthrough agonist GPCR antibodies targeting dopamine receptors in cancer. Other functional single domain antibodies targeting checkpoint inhibitors, cancer metabolism, immune and tumor associated antigens are incorporated as modules in our multi-specific antibody pipeline.

Our KisoSeek screening technology, KisoMouse platform, and KisoBody multispecific antibody format work as interlocking platforms to produce best-in-class therapeutic antibodies.

• KisoSeek: NextGen Sequencing/AI driven structural antibody screening

• KisoMouse: Single domain antibody transgenic mouse platform

• KisoBody: Multifunctional, multi-specific antibody format to enhance efficacy and safety by targeting multiple antigens simultaneously

MedBiome

Bill Cheliak Ottawa, ON Category: Therapeutic

Presented by: University of Ottawa, Faculty of Medicine

MedBiome has a unique technology, called RapidAIM, to quickly identify compounds that modulate production of specific metabolites in living human microbiomes. Based on these results, the Company develops therapeutics to modulate the production of microbiome metabolites beneficial to human health.  RapidAIM can also be used to stratify patients based on their microbiome responses in order to optimize therapeutic outcomes. The Company has programs in four disease areas (IBD, Alzheimer’s Disease, Chronic Kidney Disease and Colorectal Cancer). MedBiome has also partnered with companies to screen their proprietary compounds against living microbiomes using the RapidAIM technology.

Mediphage Bioceuticals

Lee Bowman, COO Toronto, ON Category: Therapeutic

Mediphage Bioceuticals is a genetic medicine company developing safe and effective cures for chronic disease. Mediphage’s unique and patented ministring DNA technology has broad applicability as a non-viral vector for gene delivery and Mediphage’s plan is to develop a pipeline of drug candidates utilizing its technology in an array of areas including oncology, T cell and B cell therapy, iPSC, gene editing and DNA vaccines. Mediphage’s first focus in on Stargardt’s disease, a form of macular degeneration with juvenile onset. Stargardt is a large market, estimated to be $780M in 2016 with expected growth to $1.6BN by 2027. Mediphage is expanding its disease focus either through development of internal therapeutic assets or through licensing of its technology with strategic partners.

My Intelligent Machines (MIMs)

Sarah Jenna, CEO Montréal, QC Category: Devices, Diagnostics & Clinical Decision Support

Presented by: Montréal InVivo

MIMs is a Montréal-based company founded in 2016 by Sarah Jenna (CEO), Mickaël Camus (COO/CTO) & Abdoulaye Baniré Diallo (CSO). Our mission is to help Bio-Pharma & Agritech companies use bioinformatics, systems biology & AI to leverage the huge amount of OMIC, clinical/phenotypical & environmental data they are generating to maximize their activities. We closed our seed round with $2.6M led by Anges Québec. We follow the Land & Expand strategy, starting with a pilot project contract that will start generating >$100k recurring revenue & expand within the company to million(s)$ recurring revenues.

Monogenic Pharmaceuticals

Steve Poirier, CEO Montréal, QC Category: Therapeutic

Presented by: Montréal InVivo

MONOGENIC Pharmaceuticals is a biopharmaceutical preclinical stage company, a spin-off of the Montréal Heart Institute following 7 years of R&D. We are focused on developing innovative and disruptive add-on to statin small molecules to control atherosclerotic cardiovascular disease (ASCVD) by helping the body to clear excess LDL-Cholesterol. MONOGENIC is now actively seeking strategic financial partners to complete a Series A investment. This investment will enable the completion of the activities necessary to reach Phase 1/2a clinical trial and prepare for the advancement and completion of our Phase 2b clinical trial. 

Morphocell Technologies

Massimiliano Paganelli, Co-Founder & Interim CEO Montréal, QC Category: Therapeutic

Presented by: Stem Cell Network

Morphocell Technologies is a pre-clinical stem cell therapeutics company driving towards making liver transplantation for liver failure obsolete. Morphocell’s encapsulated liver tissue (ELT) is a patent pending, allogeneic solution to address organ shortage and the narrow treatment windows that exist for treating liver failure. $1M in seed funding has significantly de-risked the technology by enabling proof of concept efficacy data and addressing key scalability hurdles in manufacturing. We are seeking $25M to complete pre-clinical safety, formulation fill finish, large animal efficacy, GMP cell line derivation, and clinical grade material manufacture towards initiation of a Phase I/IIa clinical trial in Canada.

Notch Therapeutics

Timothy Key, Director, Business Operations Toronto, ON Category: Therapeutic

Presented by: Centre for Commercialization of Regenerative Medicine

Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.

Notogen

Gary Margolis, CEO Toronto, ON Category: Therapeutic

Notogen is an early-stage biotechnology company developing a novel biological therapy (NTG-101) for degenerative disc disease (DDD), a disease indication with a large unmet need. There are currently no approved disease modifying treatments for DDD, with treatment options being primarily limited to pain relief (largely opioid prescriptions) and/or highly invasive and costly surgeries such as spinal fusions. Notogen has published impressive large animal in vivo data, has had a successful pre-IND meeting with the FDA and, as a result of a recent US$12.5M convertible note financing, has commenced work with US commercial manufacturing organizations to produce cGMP-grade NTG-101 in advance of an expected IND filing with the FDA in Q4-2020.  Notogen is now looking to raise a Series A equity round to finance its Phase I/IIa clinical trials and beyond.

Protaxis Therapeutics Inc.

James B. Jaquith, COO Toronto, ON Category: Therapeutic

Presented by: Children’s Hospital of Eastern Ontario

PROTAXIS Therapeutics is an early-stage platform company focused on the development of novel next-generation IAP-based therapeutic agents. Having broad therapeutic potential, the Inhibitor of Apoptosis (IAP) Proteins are a family of highly conserved proteins, three of which (XIAP, cIAP1 and cIAP2) have E3 ubiquitin ligase activity via their RING domains. The PROTAXIS founders are world leading experts in the biology and therapeutic development of IAP antagonists, having successfully advanced both an antisense oligonucleotide AEG35156 and a small molecule antagonist AEG40826 (HGS1029) into international multicenter clinical trials.

Ripple Therapeutics

Tom Reeves, President & CEO Toronto, ON Category: Therapeutic

Ripple Therapeutics is a spin out from Interface Biologics with a sustained release non-polymeric prodrug delivery platform that provides for zero order release kinetics via surface erosion. The lead product is a fully degradable intravitreal dexamethasone prodrug implant targeting retinal edema. We have a strong pre-clinical data set and the FDA has confirmed an abbreviated regulatory path via 505(b)(2). We are in the process of raising a ~$25M Series A round which will allow us to complete the Phase II clinical trial for our lead program as well as to continue to develop our technology platform.

Satellos

Frank Gleeson, CEO Toronto, ON Category: Therapeutic

Presented by: Stem Cell Network

Satellos is a muscle regeneration company developing small molecules to treat muscle wasting disorders associated with genetic conditions, trauma and diseases of ageing. These disorders represent billion dollar markets from orphan to mass market indications. Our scientific expertise is based identifying and drugging of regulatory pathways which modulate muscle stem cells to enable regeneration. Founded in 2018, Satellos is seeking a Series A financing of $30M to undertake pre-clinical and initial clinical development activities.

StemAxon

Gilbert Bernier, CEO Montréal, QC Category: Therapeutic

Presented by: Stem Cell Network

StemAxon™ is a biotechnology company which specializes in stem cell technology and neurodegenerative diseases. Our two areas of focus are Macular Degeneration and Alzheimer's disease.

StemAxon™ has 5 main developing technologies:

1. Macular Transplantation Therapy (in Pre-clinical trials).

2. Novel Treatment for wet ARMD and other ocular neo-vascular diseases using a new molecule that does not act through VEGF signaling (toxicity tests in 2020).

3. Novel Treatment for Alzheimer’s disease; Pharmacology and Gene Therapy (Pre-Clinical Proof of Concept in human cortical neurons)

4. Alzheimer’s disease drug screening platform.

5. Molecular diagnostic of Sporadic Alzheimer’s disease.

Triumvira Immunologics

Christopher Helsen, Director Research and Development, Head of Platforms Hamilton, ON Category: Therapeutic

Presented by: Centre for Commercialization of Regenerative Medicine

Triumvira Immunologics, Inc. is an immunotherapy company developing novel T cell therapies that are safer and more efficacious than current cancer treatments. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients. Triumvira is raising Series A financing to commence phase I trials.